Product Pathways - Growth Factors/Cytokines
Mouse His6Interleukin-25/IL-17E (mHis6IL-25) #11996
|11996LC||50 µg (With Carrier)||---||In Stock||---|
|11996LF||50 µg (Carrier Free)||---||In Stock||---|
|11996SF||10 µg (Carrier Free)||---||In Stock||---|
|11996SC||10 µg (With Carrier)||---||In Stock||---|
Already purchased this product? Write a Review.
Recombinant mouse His6IL-25 (mHis6IL-25) Val17-Ala169 (Accession #NP_542767) was expressed in human 293 cells at Cell Signaling Technology.
Recombinant N-terminally His6-tagged mIL-25 has a calculated MW of 20,051 Da. DTT-reduced protein migrates as a 24-31 kDa polypeptide. The nonreduced cystine-linked homodimer migrates as a 46-50 kDa protein. Lower mobility and heterogeneity in SDS-PAGE are due to glycosylation. The expected amino terminus of recombinant mHis6IL-25 was verified by amino acid sequencing.
>97% as determined by SDS-PAGE of 6 μg reduced (+) and nonreduced (-) recombinant mHis6IL-25. All lots are greater than 97% pure.
The bioactivity of recombinant mHis6IL-25 was determined in mouse splenocyte and HT-29 cell cytokine secretion assays. The ED50 of each lot is between 0.5-1.5 ng/ml in mouse splenocyte cells and 0.25-1.5 ng/mL in HT-29 cells.
The purity of recombinant mHis6IL-25 was determined by SDS-PAGE of 6 µg reduced (+) and nonreduced (-) recombinant mHis6IL-25 and staining overnight with Coomassie Blue.
IL-13 production from mouse splenocytes cultured with mHis6IL-25 was assessed. Mouse splenoyctes were treated with increasing concentrations of mHis6IL-25 for 72 hr. Cell supernatants were then harvested and assayed for IL-13 by ELISA, and the OD450 was determined.
GRO α production from HT-29 cells cultured with mHis6IL-25 was assessed. HT-29 cells were treated with increasing concentrations of mHis6IL-25 for 24 hr. Cell supernatants were then harvested and assayed for GRO α by ELISA, and the OD450 was determined.
Less than 0.01 ng endotoxin/1 μg mHis6IL-25.
With carrier: Lyophilized from a 0.22 μm filtered solution of mHis6IL-25 in 20 mM Tris, pH 7.2 containing 20 μg BSA per 1 μg mHis6IL-25. Carrier free: Lyophilized from a 0.22 μm filtered solution of mHis6IL-25 in 20 mM Tris, pH 7.2.
IL-25, also known as IL-17E, is a member of the IL-17 superfamily of cytokines. IL-25 is expressed in epithelial cells, CD4+ T cells, mast cells, and eosinophils (1). Many cell types are responsive to IL-25, including T cells, macrophages, and epithelial cells (1). The receptor for IL-25 consists of a heterodimer of IL-17RA and IL-17RB (1,2). IL-25 promotes Th2 type immune responses by induction of IL-5, IL-4, and IL-13 and may contribute to allergic inflammation and asthma (1-3). IL-25 has also been shown in research to promote Th9 cell activation and induce apoptosis in breast cancer cells (4,5).
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.